Photo by soberanes from unsplash
Sacral neuromodulation (SNM) is third‐line therapy approved for urge urinary incontinence (UUI) and urgency, and nonobstructive urinary retention. Multiple sclerosis (MS) patients often suffer from neurogenic lower urinary tract dysfunction… Click to show full abstract
Sacral neuromodulation (SNM) is third‐line therapy approved for urge urinary incontinence (UUI) and urgency, and nonobstructive urinary retention. Multiple sclerosis (MS) patients often suffer from neurogenic lower urinary tract dysfunction (NLUTD). The utility of SNM in the MS population is limited by magnetic resonance imaging (MRI) incompatibility as routine MRIs to evaluate for disease progression are required. The Axonics System is the first Food and Drug Administration‐approved SNM device that is 1.5/3 T full‐body MRI‐conditionally safe. This study seeks to investigate the symptomatic improvement in MS patients after implantation of the Axonics System.
Journal Title: Neurourology and Urodynamics
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!